GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Exosome secretion in breast cancer progression

$467,195
Alissa M Weaver · Vanderbilt University · R01 · FY2016 · CA

Biology of AR+ prostate cancer metastases and the role of the microenvironment

$467,174
Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Quantitative histopathology for cancer prognosis using quantitative phase imaging on stained tissues

$467,172
Mark A Anastasio · University Of Illinois At Urbana-Champaign · R01 · FY2023 · CA

Comprehensive atlas of advanced adenomas and their surrounding primed colon: A multi-omics evaluation and clinical impact assessment

$467,151
William M Grady · Fred Hutchinson Cancer Center · U54 · FY2024 · CA

Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy

$467,098
J. Silvio Gutkind · University Of California, San Diego · R01 · FY2021 · DE

Therapeutic targeting of glutamine metabolism in MDS

$467,092
Marina Y Konopleva · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA

Role of Tumor Stem Cells Recurrent Prostate Cancer

$467,053
Gary Smith · Univ Of North Carolina Chapel Hill · P01 · FY2011 · CA

Role of breast cancer secreted miRNA in brain metastasis

$467,050
Shizhen Emily Wang · University Of California, San Diego · R01 · FY2025 · CA

Differences in Tumor Biology of Multiple Myeloma in Association with African Ancestry

$467,019
Linda B Baughn · Mayo Clinic Rochester · R37 · FY2024 · CA

Chemical Probes for In Vivo Fibrin Imaging

$466,961
Zhaoda Zhang · Massachusetts General Hospital · R01 · FY2015 · CA

Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation

$466,898
Xinna Zhang · Indiana University Indianapolis · R01 · FY2023 · CA

Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation

$466,898
Xinna Zhang · Indiana University Indianapolis · R01 · FY2025 · CA

Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors

$466,837
Seth M Pollack · Northwestern University At Chicago · R01 · FY2024 · CA

Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer

$466,819
Wenbin Lin · University Of Chicago · R01 · FY2023 · CA

Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer

$466,819
Ralph R Weichselbaum · University Of Chicago · R01 · FY2025 · CA

Znf740 in the regulation of CD8+T cell exhaustion

$466,803
Venuprasad K Poojary · Ut Southwestern Medical Center · R01 · FY2023 · CA

Developmental studies to inform clinical stratification and targeting of SHH MB

$466,787
Alexandra L. Joyner · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma

$466,752
Reuben J Shaw · Salk Institute For Biological Studies · P01 · FY2023 · CA

Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma

$466,751
Reuben J Shaw · Salk Institute For Biological Studies · P01 · FY2025 · CA

Gene Edited and Engineered Tumor Cell Therapeutics for Cancer

$466,689
Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2021 · NS

Neoadjuvant immunotherapy approaches to early stage melanoma

$466,650
Meenhard Herlyn · Wistar Institute · P50 · FY2021 · CA

Functional Cooperation of Tissue Factor and Integrins

$466,643
Wolfram Ruf · Scripps Research Institute, The · R01 · FY2015 · HL

Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer

$466,587
Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2024 · CA

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer

$466,517
Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer

$466,514
Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA